尽管目标价下调，该公司仍维持对其股票的买入评级。根据InvestingPro的分析，基于公平价值指标，该股票似乎被低估。此次调整反映了对Bicycle Therapeutics药物开发管线的重新评估。 该公司分析师指出，更新后的模型考虑了公司当前的管线状况。虽然InvestingPro数据显示该公司正在快速消耗现金，毛利率较低，但特别关注了正在开发多种用途的药物候选者zele。

B.Riley对Bicycle Therapeutics的目标价做出了重大调整，将其从$28.00下调至$17.00，同时维持中性评级。这是在zelenectide pevedotin的临床数据发布后做出的，该数据未能达到分析师设定的预期。然而，该公司承认Bicycle Therapeutics在过去十二个月内实现了48.6%的令人印象深刻的收入增长。

A comprehensive evaluation of state efforts to improve cycling and expose its persistent challenges was released earlier this ...

The volunteer mechanics dedicate their time without compensation, driven by the memory of their own first bikes and the ...

Luke Hoffman, Iowa Bicycle Coalition director since October 2023, says he's just getting started on boosting safety, ...

Siaya man mysteriously fell off his bicycle and died instantly on Sunday 22nd December. He had attended a football match at a ...

In the last three months, 8 analysts have published ratings on Bicycle Therapeutics BCYC, offering a diverse range of ...

Hear from Iowa Bicycle Coalition executive director Luke Hoffman as he discusses the organization’s advocacy for safe ...